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Abstract
Background: Between 2000–2007, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) delivered more than 1.9
billion treatments to nearly 600 million individuals via annual mass drug administration (MDA) of anti-filarial drugs
(albendazole, ivermectin, diethylcarbamazine) to all at-risk for 4–6 years. Quantifying the resulting economic benefits of this
significant achievement is important not only to justify the resources invested in the GPELF but also to more fully
understand the Programme’s overall impact on some of the poorest endemic populations.
Methodology: To calculate the economic benefits, the number of clinical manifestations averted was first quantified and
the savings associated with this disease prevention then analyzed in the context of direct treatment costs, indirect costs of
lost-labor, and costs to the health system to care for affected individuals. Multiple data sources were reviewed, including
published literature and databases from the World Health Organization, International Monetary Fund, and International
Labour Organization.
Principal Findings: An estimated US$21.8 billion of direct economic benefits will be gained over the lifetime of 31.4 million
individuals treated during the first 8 years of the GPELF. Of this total, over US$2.3 billion is realized by the protection of
nearly 3 million newborns and other individuals from acquiring lymphatic filariasis as a result of their being born into areas
freed of LF transmission. Similarly, more than 28 million individuals already infected with LF benefit from GPELF’s halting the
progression of their disease, which results in an associated lifetime economic benefit of approximately US$19.5 billion. In
addition to these economic benefits to at-risk individuals, decreased patient services associated with reduced LF morbidity
saves the health systems of endemic countries approximately US$2.2 billion.
Conclusions/Significance: MDA for LF offers significant economic benefits. Moreover, with favorable program
implementation costs (largely a result of the sustained commitments of donated drugs from the pharmaceutical industry)
it is clear that the economic rate of return of the GPELF is extremely high and that this Programme continues to prove itself
an excellent investment in global health.
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Introduction
As a leading cause of permanent and long-term disability
worldwide, the parasitic infection lymphatic filariasis (LF) imposes a
severe physical and socioeconomic burden on 1.3 billion at-risk
personsin 83 endemiccountries.Anestimated 120millionpeople are
already infected with LF, with about 40 million suffering from overt
clinical disease manifested as painful severe swelling due to
lymphedema (generally an accumulation of lymphatic fluid in the
limbs)andhydrocele(fluidaccumulationinthescrotalsac).Toridthe
world of this debilitating disease, the Global Programme to Eliminate
Lymphatic Filariasis (GPELF) was begun in 2000 to guide endemic
countries in implementing single-dose, once-yearly mass drug
administration (MDA) using a combination of either albendazole+
ivermectin or albendazole+diethylcarbamazine (DEC) for an antic-
ipated 4–6 years. Use of this effective strategy for LF elimination has
become feasible because of the drug donations of albendazole and
ivermectin from their pharmaceutical manufacturers, GlaxoSmithK-
line and Merck & Co., Inc, respectively.
Over the first 8 operational years of the GPELF (2000–2007),
more than 1.9 billion MDA treatments were administered to
approximately 570 million individuals in 48 countries. This
significant programmatic achievement has resulted in a notably
beneficial impact on the health of endemic populations [1]. More
than 6 million cases of hydrocele and 4 million cases of
lymphedema have been prevented, resulting in over 32 million
disability-adjusted life years (DALYs) averted and numerous
quality-of-life benefits attained.
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significance of these achievements. Specifically, how much
financial cost and loss of income is prevented over the lifetimes
of individuals protected from LF due to the first 8 years of the
GPELF? And, what cost savings do national health systems realize
from the reduction in LF infection and morbidity?
To date, few attempts have been made to examine LF from an
economic perspective, particularly on a global level. Such data,
however, is invaluable to policymakers, public health administra-
tors, and program funders who may already be convinced that LF
is a ‘best buy’ in global health but who lack precise estimates to
support their conviction. This study offers such an economic
analysis and estimates that following the first 8 years of the
GPELF, US$21.8 billion of economic benefits will be gained by LF
infected and non-infected individuals in MDA-treated areas, in
addition to US$2.2 billion in health systems savings. Furthermore,
though this economic assessment has not included the value of the
many ancillary benefits on other concurrent infections that are
effectively treated by the anti-LF drug regimens, it still leads to a
far better understanding of the GPELF’s true overall impact on
one of society’s most debilitating and widespread tropical diseases.
Methods
Data Sources
Key data sources are listed below, though specific sources are
cited throughout the paper:
1) LF at-risk, infected, and treated population estimates are taken from
The World Health Organization’s Weekly Epidemiological
Record and WHO Annual Reports between 2000–2008
[2,3,4,5,6,7,8].
2) Health impact estimates are taken from The Global Programme to
Eliminate Lymphatic Filariasis: Health Impact after 8 Years [1].
3) Direct treatment costs are based on published literature (cited as
presented) in relation to medicine prices gathered from
Health Action International and Management Sciences for
Health [9,10].
4) Indirect loss of labor estimates are based on published literature
as cited.
5) Wage and income estimates come from the International Labour
Organization’s LABORSTA database [11], the World Bank’s
World Development Indicators Online [12], and minimum wage
estimates from the International Labour Organization [13]
and the US Department of State’s Country Reports on Human
Rights Practices 2008 [14].
6) Official currency exchange and inflation rates are from the
International Monetary Fund’s World Economic Outlook 2008
database [15].
Population Groups Analyzed for Economic Benefits from
the GPELF – the ‘‘Benefit Cohort Population’’
For this analysis, two broad groups of individuals are recognized
as economically benefitting from the MDA treatment given during
the first 8 years of the GPELF:
N Those protected from acquiring infection (and subsequent
disease [specifically, hydrocele and/or lymphedema]);
N Those already infected but protected from disease progression.
These two groups can be segmented into four sub-populations
(detailed below and summarized in Table 1); together, they
constitute the ‘‘benefit cohort population’’.
Population estimates for each sub-population were calculated
using the same base figures and key assumptions as described
previously [1]; namely that 10% of the at-risk population is
actually infected with LF, that this ratio would remain constant in
the absence of MDA, and that the relative frequency of the clinical
disease syndromes will also remain stable among those infected
individuals.
Individuals protected from acquiring infection (and
subsequent LF disease).
N Newborns in MDA treated areas who are protected
from infection over their lifetimes: The number of
babies born into LF treatment areas who likely would have
become infected in the absence of MDA was calculated for each
country covered by the GPELF between 2000–2007 based on the
rates of surviving newborns, the levels of infection in at-risk
populations, and the decreases in post-MDA infection exposure
rates [1,16]. These calculations resulted in the number of
protected newborns being 6.6 million.
Of all these babies who were protected from LF infection, an
estimated 12.5% would have progressed to lymphedema and
20.8% to hydrocele; the remaining 66.7% would have had
subclinical disease [1]. For this study, it is assumedthat only individuals
with clinical disease (lymphedema or hydrocele) would have incurred any
economic burden. As previously published, an estimated 1.4 million
cases of hydrocele and 0.8 million cases of lymphedema would
have been averted in newborns between 2000–2007 in MDA
treated areas [1].
N Other individuals protected by MDA from acquiring
LF infection: In the absence of MDA, approximately 10% of
the at-risk population is infected with LF [1]. To maintain this
steady-state proportion in a dynamic population, non-infected
individuals must continue to acquire infection through LF
transmission at a rate sufficient to ‘replace’ those who leave the
population (i.e. through death) each year. The size of this
Author Summary
Lymphatic filariasis (LF), commonly known as ‘elephantia-
sis’, is one of the world’s most debilitating infectious
diseases. In 83 countries worldwide, more than 1.3 billion
people are at risk of infection with an estimated 120
million individuals already infected. A recent publication
reviewing the health impact of the first 8 years of the
Global Programme to Eliminate Lymphatic Filariasis
(GPELF) demonstrated the enormous health benefits
achieved in populations receiving annual mass drug
administration (MDA), as a result of infection prevented,
disease progression halted, and ancillary treatment of co-
infections. To date, however, no studies have estimated
the economic value of these health benefits, either to the
individuals or the societies afflicted with LF. Our study
estimates that US$21.8 billion will be gained among
individuals benefitting from just the first 8 years of the
Global Programme, and an additional US$2.2 billion will be
saved by the health systems of endemic countries.
Treating endemic populations is possible at very low cost –
particularly because of the generous drug donations from
two pharmaceutical companies – but results in enormous
economic benefits. Findings from this study yield a much
clearerunderstandingtheGPELF’sfulleconomicimpactand
strengthen the conviction that it is a ‘best buy’ in global
health.
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infected patient deaths in the year; this total was calculated by
multiplying the number of infected individuals who either had
clinical disease or were expected to progress to clinical disease
by the age- and country-specific mortality rates derived from
the World Health Organization’s Life Tables for WHO Member
States [17].
Between 2000–2007 in the populations covered by the
GPELF, over 550,000 infected individuals who either had
clinical disease or were expected to progress to clinical disease
died; therefore, the same number of replacement infections would
have been expected to occur over the same time-period to
maintain the overall steady-state infection ratio in the at-risk
population. However, because of MDA, these replacement
individuals will be protected from acquiring infection and thus
will accrue the benefits of averting clinical disease. As
described elsewhere [1], the full protective benefits of MDA
are likely not attained immediately after the first MDA, so
calculations are based both on the numbers of people treated
in each country each year and also on the assumption (derived
from available transmission studies [1]) that only 50% would
be protected after the first round of MDA treatment, 75% after
the second, 87.5% after the third, 94% after the fourth, and
100% after the fifth. As a result, an estimated 480,000
individuals were protected from acquiring infection (and
subsequent clinical disease) between 2000–2007.
All the protected individuals in these two ‘benefiting popula-
tions’ need not themselves have been directly treated during the
MDA, as high MDA coverage in at-risk populations will drastically
reduce the rate of transmission and, therefore, infection in
untreated individuals as well [18,19]. Indeed, reports from the
World Health Organization do indicate high MDA coverage
averaging more than 70% overall, with several regions and
countries covering more than 90% [2,3,4,5,6,7,8].
Individuals already infected with LF but protected by
MDA from progression of disease.
N Individuals with subclinical disease at the time of MDA:
Previous studies have shown that approximately two-thirds of
individuals infected with LF will have subclinical disease [16] and
about half of these are expected to progress to overt clinical disease
in their lifetimes [1]. In order to remain conservative for the
present analysis, it is estimated that MDA halts disease progression
in only 50% of those who would have progressed to clinical disease [20]—
and that disease is apportioned as described previously: 62.5%
being hydrocele, 37.5% being lymphedema.
Since this study assumes that the only individuals incurring
economic costs due to LF are those with clinical disease, the only
individuals with subclinical disease whose benefits from MDA are
tallied in this analysis are those who would have been expected to
progress to clinical disease. Previous estimates are that 9.4 million
subclinical cases were prevented from progressing to hydrocele
and lymphedema between 2000–2007 [1].
N Individuals with clinical disease at the time of MDA.
Of the 10% of the at-risk population who are infected,
approximately one-third has overt clinical disease— again,
with the majority of those manifesting hydrocele (62.5%) and
the remaining, lymphedema. It was previously estimated that
between 2000–2007, approximately 570 million at-risk
individuals, including 57 million with LF infection, received
MDA [1]; therefore, roughly 19 million individuals with overt
clinical disease received MDA.
It is still uncertain to what extent MDA improves morbidity in
those already suffering from hydrocele or lymphedema, but
recent studies provide preliminary evidence of the positive
effects of repeated rounds of MDA on the progression or even
reversibility of LF morbidity. Specifically, MDA has been
shown to alleviate the number of acute ADL episodes
associated with LF by 59–88% after just two rounds of
annual MDA with DEC with and without albendazole
[21,22,23]. The effects of MDA on chronic disease, however,
are more uncertain. A study in Papua New Guinea resulted in
complete reversal of 87% of hydrocele and 69% of leg
lymphedema cases after 5 annual rounds of DEC+ivermectin
or DEC alone [24], and studies in Indonesia [25,26] and
Tanzania [27] using DEC, provide evidence of an improve-
ment or complete disappearance of clinical manifestations by
62–90% after 2–4 rounds of annual MDA. However, other
studies have failed to show such significant clinical benefits
from MDA [28,29,30]. While evidence of acute and chronic
disease regression using a combination of ivermectin+alben-
dazole or ivermectin alone is even less well documented, a
recent report from Tanzania indicates that MDA (using
albendazole+ivermectin) lessens the frequency and severity of
ADL episodes by a significant degree. The same report also
finds that approximately 15% of hydrocele cases and 98% of
lymphedema cases had shown improvement after 4 annual
rounds of MDA treatment using ivermectin+albendazole
[31].
Because of these uncertainties, the base analysis of this study
used a low-end estimate of 50% reversal in the frequency of
acute ADL episodes. For chronic disease, a reasonably
Table 1. Sub-populations of the ‘‘Benefit Cohort Population.’’
Population Group Subgroup Definition
1. Individuals protected
from acquiring infection
(and subsequent disease)
a. Newborns Babies born into MDA treated areas and whose entire lives are protected
from potential LF infection and morbidity
b. Other individuals
protected from infection
Individuals who would have acquired infection but are protected
because of interrupted transmission of LF resulting from MDA
2. Individuals infected with
LF but protected from
progression of disease
a. Subclinical disease Patients with subclinical infection at the time of MDA who are
protected from progression to clinical disease as a result of MDA
b. Clinical disease Individuals with clinical disease at the time of MDA who are either protected from
worsening of their disease or actually undergo improvement as a result of MDA
doi:10.1371/journal.pntd.0000708.t001
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15% of lymphedema cases were considered reversible after 5
rounds of MDA involving either DEC or ivermectin in the
treatment regimen. However, in order to take into account
the uncertainties of the outcomes of MDA on pre-existing
clinical morbidity, a sensitivity analysis was also conducted
ranging from 0% reversal to 90% reversal as per the lower
and upper boundaries cited by the literature.
Calculating the Total Economic Benefits of the GPELF
The previous section defined a 4-part benefit cohort population as
the group of protected individuals who will realize economic
benefits as a result of MDA activity between 2000–2007. The total
economic impact of the GPELF, however, extends over a much
longer period than these first 8 years because protection from LF
infection or disease progression is a lifelong benefit. It is therefore
necessary to aggregate the total economic benefit gained over the
projected remaining lifetime of the benefit cohort population.
To estimate this total, a general formula (Figure 1) was applied
and calculated independently for each country to accommodate
country specific differences in several key variables (life expectan-
cy, mortality rate, direct and indirect costs). All calculated costs
and benefits are discounted to the base year of 2008.
Duration of economic benefits. The duration of economic
benefits depends on the age of onset of clinical disease (assumed as
20 years old [1] in each country), the average life expectancy
(differing by country), and the age at which an individual received
MDA treatment. In this model, for each subgroup population, a
same single average age for each country was used to encompass the
entire age range of individuals within the benefit cohort population at
the time of treatment, with the recognition that some of those
receiving treatment will be younger than the average age and
some older (Figure 2).
N Newborns (Group 1a, Table 1) did not actually receive
MDA treatment but are considered protected from the time of
birth once transmission has been interrupted; thus their
average age at the time of treatment is 0. However, because
the average age of clinical disease onset is 20 years old [1],
benefits for newborns do not accrue until 20 years after birth because on
average, no clinical disease and hence, economic costs will be
incurred before that age;
N For other individuals protected from LF infection
(Group 1b), MDA treatment is estimated to occur at 20 years
of age on average.
N Infected individuals with subclinical disease (Group
2a) are also estimated to be 20 years old on average when they
receive MDA. Though subclinical infection is common in early
childhood, this model assumes that the average age of treated
(and thus protected) subclinical patients is 20 years.
Figure 1. General formula for calculating economic benefits. The formula was applied and calculated independently for each country to
accommodate country-specific differences in several key parameters (i.e. life expectancy, mortality rate, direct and indirect costs). All calculated costs
and benefits are discounted by 3% per year to the base year of 2008.
doi:10.1371/journal.pntd.0000708.g001
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drocele or lymphedema, Group 2b) are estimated to be 30
years old on average when they receive MDA. This estimate
implies that clinical-disease patients have been living with their
condition for an average of 10 years, since onset of clinical
disease is taken as 20 years of age.
Population size. This study projects the total economic
impact of the first 8 years of the GPELF by aggregating the
economic benefits over the lifetime of the 2000–2007 benefit cohort
population. To remain consistent with this study’s goal of only
estimating the GPELF’s economic achievements following these 8
years, no projections are made for the growth of MDA treatments
after 2007 or any resulting economic benefits to new individuals
treated beyond the benefit cohort population.
Year-to-year, the size of the benefit cohort population will decrease
because of country-specific mortality and average life expectancy.
Because the model assumes this non-static population over time,
the economic-benefit denominator must be analyzed in person-years,
which is the sum of each year lived by each individual in the benefit
cohort population. Table 2 shows that the first 8 years of the GPELF
will provide over 1.1 billion person-years of economic benefit
during the lifetime of the 31.4 million individuals in the benefit cohort
population.
Economic costs prevented. Economic costs are comprised
of direct treatment costs and indirect labor costs. Economic costs are
further segmented in each sub-population group (Table 1)b y
disease type (acute or chronic) and morbidity type (hydrocele or
lymphedema). Key model assumptions and estimates, weighted by
country–specific rates, are summarized in Table 3.
N Direct treatment costs refer to costs (e.g., for medicines,
consultation fees, transport, food, accommodation) that are
incurred when an individual with clinical morbidity seeks
treatment.
Patients seeking treatment for acute inflammatory attacks
caused by LF usually receive pain relieving and anti-inflamma-
tory medicines, with or without systemic antibiotics [32].
Chronic disease sufferers may also seek care following bouts of
severepainand swellingand receive a similar treatment package.
Chronic patients may also purchase bars of soap in accordance
with prevailing lymphedema management strategies [32].
Median international reference prices for a course of
amoxicillin, ibuprofen, and paracetamol were collected from
Health Action International [9] and Management Science for
Health [10] to approximate public and private sector costs of
medicines across GPELF countries. Primary data show that for
individuals seeking treatment at health facilities for LF,
medicines, on average, comprise 50% of the total treatment
cost, consultation fees 30%, and transport, food, and
accommodation the remaining 20% [33,34,35,36,37]. For
self-treatment individuals, only the medicine costs were
attributed to total treatment costs.
Acute disease refers to periodic, recurring attacks of acute
adenolymphangitis (ADL), defined by signs and symptoms of
Figure 2. Duration of economic benefits. Economic benefits are calculated only for the benefit cohort population receiving MDA between 2000–
2007; however, the benefits are gained until the end of their lifetime. For modeling purposes, single average ages were used to encompass the entire
age range of individuals in each population subgroup, realizing that some individuals will be above this average age at the time of treatment, and
some below. The size of each subgroup decreases each year based on country and age-specific mortality rates.
doi:10.1371/journal.pntd.0000708.g002
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Population Group Population Subgroup
Benefit Cohort
Population Size
(2000–2007) (millions)
Average Age
of MDA
Treatment
1
Average
Years of
Economic
Benefit
2
Person-Years
(Lifetime)
(millions)
3
1. Protected from acquiring
infection (and subsequent disease)
a) Newborns 2.2 - 43 83.8
b) Protected from infection 0.5 20 43 15.7
Subtotal 2.7 -- 99.5
2. Protected from disease
progression
a) Subclinical morbidity 9.4 20 43 388.6
b) Clinical morbidity 19.3 30 33 626.6
Subtotal 28.7 - - 1,015.3
Total 31.4 - - 1,114.8
1Newborns, although not actually treated with MDA, are assumed protected from infection at the time of birth and protected from clinical disease from 20 years of age.
2Based on average life expectancy of 63 years, weighted by country-specific rates and Benefit Cohort Population in each country.
3Sum of each year lived by each individual in the Benefit Cohort Population. Equal to (Benefit Cohort Population)6(Average Years of Economic Benefit), adjusted for
annual mortality.
doi:10.1371/journal.pntd.0000708.t002
Table 3. Epidemiological and cost estimates used in the Economic Benefit Model.
Parameter
Type
Acute or
Chronic
Disease
Associated
Cost-Type Rate or Proportion
Regional
Variation
Hydrocele Avg.
Estimate
1
Lymphedema
Avg. Estimate
1
Sources, Key
Assumptions
Epidemiological Acute Disease Direct and
Indirect
% of clinical LF patients
with ADL
Global estimate
2 70% [45–90%] 95% [90–95%] [33,35,39,40,41,
42,43,44,45]
% of patients with ADL
seeking treatment
Global estimate, India
excepted
3
65% [55–70%] 65% [55–70%] [33,34,35,42]
# of ADL episodes per
patient (w/o MDA)
Global estimate
2 2 [0–7] 4 [0–7] [33,35,39,40,41,
42,43,44,45]
% of ADL episodes
prevented by MDA
Global estimate
2 50% [15–88%] 50% [15–88%] [21,22,23], varies
by MDA round
Indirect Cost Avg. duration of ADL
episode (days)
Global estimate
2 4 [0–9] 4 [0–9] [33,35,39,40,41,
42,43,44,45]
% of work hours lost per
day due to ADL
Global estimate
2 75% [50–93%] 75% [50–93%] [40,42,44,51]
Chronic Disease Direct and
Indirect
% of Chronic disease
patients seeking treatment
Global estimate,
India excepted
3
40% [20–50%] 50% [30–55%] [34,36,37,38]
% of Chronic disease patients
benefiting from MDA
Global estimate
2 10% [0–87%] 15% [0–69%] [24,25,26,27,28,
31,55], varies by
MDA round
Indirect Cost % of work hours lost per
day due to chronic disease
Global estimate
2 15% [13–17%] 20% [15–22%] [36,37,40]
Cost Acute Disease Direct Cost Avg. treatment cost per
episode
Country-specific
estimate
4
$1.5 [$0.25–
$5.20]
$1.5 [$0.25–
$5.20]
[9,10,33,34,35,
36,37]
Chronic Disease Direct Cost Avg. treatment cost
per year
Country-specific
estimate
4
$2.9 [$0.55–
$10.05]
$4.3 [$0.85–
$15.00]
[9,10,33,34,35,
36,37]
Acute and
Chronic Disease
Indirect Cost Avg. wage per day Country-specific
estimate
4
$1.05 [$0.30–
$5.60]
$1.05 [$0.30–
$5.60]
[11,12,
13,14]
Chronic Disease Indirect Cost Work days per year Global estimate
2 300 [300–365] 300 [300–365] Assuming 6
workdays/week
1Weighted average over all GPELF countries.
2Global estimate indicates a standard rate or proportion was utilized for each GPELF country. This is primarily due to a lack of supporting country-specific data.
3Indicates a standard rate or proportion was utilized for each GPELF country with the exception of India where more primary data was available and suggested
estimates differ from other GPELF regions.
4Estimates are country-specific and gathered from public online international database sources.
doi:10.1371/journal.pntd.0000708.t003
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limbs with constitutional symptoms such as fever, nausea, and
vomiting [35,38,39].
Approximately 70% of hydrocele patients experience at
least 1 ADL episode per year with an average of 2. For
lymphedema patients, almost 95% experience at least 1
episode with an average of 4. The number of episodes for
both morbidities, however, can be up to 7 or higher. Each
ADL episode lasts on average 4 days although the duration can
range to 9 or more days [33,35,39,40,41,42,43,44,45].
The proportion of individuals with ADL episodes who seek
treatment – whether at a health facility, traditional healer, or
through self-treating with medicine – ranges from 55% to 70%
depending on the country and region. Similarly, the preferred
treatment source and related costs are highly region-specific. In
WHO-AFRO, self-treatment and traditional healers may be
used in 70% of cases, leading to a weighted average cost across
all sources of US$0.90 per ADL episode treated. In
comparison, WHO-SEARO has an average weighted cost of
US$1.40 per episode treated, largely due to the higher cost and
proportion of treatment seeking in urban areas and private
health facilities in India [33,34,35,42]. WHO-WPRO has an
even greater average weighted cost of $4.90 due to higher
wages and standard of living costs in this region. Across all
GPELF countries, the overall weighted average of treatment
seeking behavior and costs for ADL was 65% and $1.50
respectively.
Chronic disease refers to individuals with overt clinical
disease in individuals with hydrocele and/or lymphedema. All
population groups with economic benefits from MDA in this
study are assumed to have (or would otherwise have acquired)
chronic disease but only a proportion of these chronic disease
patients incur acute ADL episodes.
The percentage of chronic disease patients who seek
treatment is also highly dependent on the country/region,
severity of disease, and availability of treatment. On average,
this study conservatively assumes that 30% of hydrocele and
35% of lymphedema patients seek treatment, although in India
these proportions are estimated at 60% and 65%, respectively,
based on the available literature. These estimates are also
weighted over time with the assumption that almost all chronic
disease patients will seek treatment in the early years of disease
morbidity but will reduce their frequency over the long-term.
Chronic disease patients are assumed to seek treatment on
average twice a year with lymphedema patients seeking and
spending slightly more. On average, treatment seeking
hydrocele patients will spend US$2.90 and lymphedema
patients US$4.30 per year for their chronic conditions
[34,36,37,38].
Hydrocelectomy (surgery to repair hydrocele) costs are
included in the chronic disease direct cost calculation. The
proportion of total direct costs related to hydrocelectomies,
however, is very small because of the relatively low frequency
of hydrocelectomies; hydrocele patients often have poor access
to surgery facilities and are further deterred by the restrictive
costs of the procedure.
N Indirect labor costs refer to income lost as a result of
reduced work hours and economic activity due to LF
morbidity. For women, economic activity also includes time
spent on domestic chores because an opportunity cost of
income-generating activity is implied. As in previous LF studies
and burden of disease analyses, indirect cost estimates were
calculated using the human capital approach, which presumes
total cost and lost output are equal to the income foregone as a
result of illness [46,47].
Approximating the income for individuals with LF is
difficult because the majority of this population is comprised
of subsistence farmers who do not participate in the formal
labor market. A variety of methods in valuing working time
have been incorporated in economic analyses of populations
with similar tropical diseases (malaria, trachoma, onchocerci-
asis), including the examination of minimum wages [48],
average value added per agricultural worker [49], and proxies
from prior studies in similar settings [50]. Based on these
methods, the combination of 3 wage sources was used in this
paper for best estimates of a fair market value of time for an
agricultural worker with LF infection: (1) The International
Labour Organization’s LABORSTA database which lists
average wages for agricultural field workers [11]; (2) The
World Bank’s World Development Indicators Online which
lists the average value added per agricultural worker [12]; (3)
The International Labour Organization’s Minimum Wages
Database and US Department of State’s Country Reports on
Human Rights Practices which list minimum wages by
occupation including agricultural and low-skilled workers
[13,14].
For countries listed by one or more sources, the lowest wage
amount was used to ensure a conservative estimate. For
countries not listed by any of the three sources, the lowest
amount within the same region was used as a proxy. In this
paper, it is assumed that all individuals with or at-risk of LF
would have been economically active otherwise and would
work 300 days per year.
Acute disease: Acute ADL episodes are severely debilitating,
with studies in India showing total economic disability for the entire
duration of the episode in 81–87% of cases versus 34–37% of
controls [40,51]. Based on these and additional case-control studies,
the present analysis assumes 75% of time spent on economic
activity is lost due to acute disease during an ADL episode
[42,44].
Chronic disease: Although LF chronic disease is less
debilitating than acute ADL episodes, chronic disease
patients still work fewer hours than equivalent non-LF
workers. While the amount of disability is strongly
correlated to the degree of disease, hydrocele patients are
estimated to work 15% less time and lymphedema patients
20% less on average [36,37,40].
N Health system costs: Comprehensive assessment of eco-
nomic costs and benefits must also include the potential savings
to the health system since decreased LF infections reduce
medical treatments needed. To estimate these patient-service
savings, country specific costs were gathered from the WHO-
CHOICE database, recording costs for a 20-minute visit to a
primary health center having a 50% regional coverage [52].
These costs were then multiplied by the number of individuals
benefiting from MDA, the percentage that seek treatment in
public health facilities, and the average number of visits per
year.
Cost Standardization: To standardize the comparison of
p r i c e sa n dw a g e so v e rd i f f e r e n ttime periods, all estimates
when necessary were adjusted to 2005 values (to correspond
to external supporting World Bank data) using national
consumer price index (CPI) data [15]. Estimates were then
converted from local currencies to US dollars using official
average 2005 exchange rates [15].
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For this study, 2008 was used as the base year for calculating
economic benefits. When calculating future benefits, however, it
is necessary to discount valuest oan e tp r e s e n tv a l u e( N P V )
under the economic principle that a dollar earned in the present
is worth more than one earned in the future. Therefore, all
annual accumulated cost savings beyond 2008 are discounted at
3% per year in accordance to guidelines set by WHO-CHOICE
[53].
Cost-Benefit Calculations
GPELF program costs can be compared with the economic
benefits calculated in this study through a cost-benefit analysis to
evaluate the efficiency and practicality of implementing the Global
Programme. Estimating program costs, however, is not the intent
of this study and such data was, therefore, sourced through our
previously published work [54]. On a macro-level, no study has yet
been conducted to estimate the total cost of the GPELF over its
first 8 years and as a result, a broader programmatic cost-benefit
analysis cannot be calculated. It is possible, however, to estimate
the cost-benefit on an individual-level using per person costs
calculated in a multi-country study of national MDA program
costs for LF including training, mapping, mobilization, distribu-
tion, monitoring, and surveillance [54]. In this study, Goldman et al.
analyzed both the average annual economic cost per person treated
(i.e. including the implied costs of donated materials and drugs –
set at US$0.19+$0.0019 for shipping per 400mg tablet of
albendazole and US$1.50+$0.0018 per 3mg tablet of ivermectin)
and also the financial cost per person treated (i.e. excluding the
costs of the donated materials and drugs) from data collected
through questionnaires and adjusted for LF-specific activities.
Donated ivermectin is used in combination with donated
albendazole in areas co-endemic for onchocerciasis in Africa plus
Yemen. DEC, which is not donated, is used in combination with
donated albendazole in all other countries and must be purchased
by national programs.
In terms of per person economic benefits, the total economic
benefits estimated over one year in this study was divided by the
total number of people treated with MDA in that same year. For
this analysis, per person economic benefits were only calculated
for the 7 countries whose program costs were also evaluated in
Goldman et al.’s study. Cost-benefit was then measured using
benefit-cost ratios (BCR), which is the per person treated benefit
divided by the per person treated cost. For standardization
purposes, the BCR reflects costs, benefits, and currencies adjusted
to the year of the most recent MDA round in Goldman et al.’s
study.
Results
Economic Benefits to the Benefit Cohort Population
During the first 8 years of LF MDA, the Global Programme
delivered nearly 2 billion treatments and reached almost 570
million individuals in 48 of the 83 identified endemic countries
(Table 4). As a result of these program achievements, 31.4 million
individuals – defined in this study as the benefit cohort population – will
gain economic benefits over their lifetime from averting direct
treatment costs and indirect lost-labor costs. Of these 31.4 million
individuals in the benefit cohort population, 2.7 million (8.6%) would
have acquired LF and subsequently progressed to clinical disease
but were protected from infection altogether because of interrup-
tion of the transmission cycle by MDA. This group comprises the
proportion of newborns (2.2 million) that are protected by virtue of
being born in MDA-treated areas, as well as other individuals in the
general population (0.5 million) protected because LF transmission
has been interrupted.
The remaining 28.7 million (91.4%) individuals are those who
were already infected at the time of MDA treatment but benefit
from halted disease progression. This population group comprises
individuals at the subclinical disease stage (9.4 million, [29.9%]) who
avoid clinical disease altogether and individuals at the clinical disease
stage (19.3 million [61.6%]) whose conditions may improve
following MDA.
As seen in Table 5, the efforts in reaching and administering
MDA to such a large population have produced extraordinary
economic benefits over the first 8 years of the GPELF. An
estimated US$21.8 billion will be saved over the lifetimes of the
31.4 million individuals who have or would have acquired clinical
disease during this timeframe. This total amount results from
summing the direct treatment costs ($1.4b) and indirect lost wages
($20.4b) prevented over the lifetime of each of the population
groups under the assumptions and estimates previously outlined in
Table 3. Direct costs for acute disease were calculated based on
Table 4. GPELF MDA treatments (2000–2007).
WHO Region GPELF Countries (2000–2007)
Individuals
Treated with
MDA (Millions)
Treated
Individuals
Infected with
LF (Millions)
1
Benefit Cohort
Population
(Millions)
AMRO Brazil, Dominican Republic, Guyana, Haiti 2.2 0.2 0.1
AFRO Benin, Burkina Faso, Cameroon, Comoros, Ghana,
Kenya, Madagascar, Mali, Niger, Nigeria, Senegal,
Sierra Leone, Tanzania (incl. Zanzibar), Togo, Uganda
51.2 5.1 2.9
EMRO Egypt, Yemen 2.7 0.3 0.2
WPRO American Samoa, Cambodia, Cook Islands, Fed. States of
Micronesia, Fiji, French Polynesia, Kiribati, Marshall Islands,
Malaysia, Niue, Papua New Guinea, Philippines, Samoa, Tonga,
Tuvalu, Vanuatu, Vietnam, Wallis and Futuna
17.4 1.7 1.0
SEARO Bangladesh, India, Indonesia, Maldives, Myanmar, Nepal,
Sri Lanka, Thailand, Timor-Leste
494.4 49.4 27.2
All Regions 48 total countries 567.9 56.8 31.4
1Assumed that 10% of at-risk population is actually infected with LF [1].
doi:10.1371/journal.pntd.0000708.t004
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MDA and the average cost incurred per episode. Chronic disease
direct costs were derived from the percentage and total number of
patients seeking treatment multiplied by the average cost spent per
treatment. Indirect costs for both acute and chronic disease were
calculated by accruing the equivalent workdays lost to LF and
multiplying this total by the average daily wage. All average costs
and rate of disease estimates were weighted annually by country-
specific estimates and with respect to total number of person-years.
On average, each individual of the benefit cohort population will
avoid nearly $700 in LF-associated costs that would have accrued
over his/her lifetime. This equates to the amount earned for 19
working days per person-year, thus preventing the loss of
approximately 6.3% of annual income (Table 6). These sums
and averages are even greater when considered in a single year-to-
year perspective, since beyond 2008, each year of economic
benefit is discounted by 3% per year.
Table 6 also shows that the infected patient sub-population
groups (i.e. clinical and subclinical) have the greatest total lifetime
benefits based on their larger proportion of the total benefit cohort
population. On a per person lifetime average, however, subclinical
(Group 2a) and ‘other protected individuals’ (Group 1b) benefits are
larger.
Figure 3 highlights the total economic benefit segmented by
cost, morbidity, and clinical presentation.
Identifying benefits by cost type. Approximately 94% of
the total economic benefits were due to the prevention of indirect
costs of lost working time and, therefore, output and income
(Figure 3, Section A). The lower proportion of direct treatment
costs (6%) was attributable to the low frequency of treatment
seeking behavior and inexpensive medicine packages relative to
the day-to-day accumulation of lost income from reduced
economic activity.
Identifying benefits by morbidity type. Economic benefits
accruing to populations protected from hydrocele are
approximately equal to those from lymphedema (Figure 3,
Section B). The estimated higher proportion of clinical disease
patients with hydrocele (62.5%) compared to lymphedema
(37.5%) offsets the greater average disability of lymphedema
patients in terms of their ADL frequency, ADL duration, and
percentage of work time lost due to disease.
Identifying benefits by clinical presentation. Preventing
chronic disease accounts for about 78% of the total economic
benefits – not unexpected given the long-term disabling nature of
LF (Figure 3, Section C). Acute episodes generally affect
individuals for only 8–12 days a year, whereas the chronic
Table 5. Total costs prevented over lifetime of Benefit Cohort Population.
Direct Costs Prevented Indirect Costs Prevented
Population Group Population Subgroup
Benefit Cohort
Population
(millions)
Acute
Disease
(US$MM)
Chronic
Disease
(US$MM)
Acute
Disease
(US$MM)
Chronic
Disease
(US$MM)
Total Costs
Prevented
(US$MM)
1. Protected from acquiring
infection (and subsequent disease)
a) Newborns 2.2 $71 $6 $207 $1,444 $1,727
b) Protected from infection 0.5 $24 $2 $75 $532 $633
Subtotal 2.7 $95 $8 $282 $1,975 $2,360
2. Protected from disease
progression
a) Subclinical morbidity 9.4 $584 $49 $1,765 $12,146 $14,544
b) Clinical morbidity 19.3 $528 $89 $1,596 $2,698 $4,911
Subtotal 28.7 $1,112 $138 $3,361 $14,844 $19,455
Total 31.4 $1,207 $146 $3,643 $16,819 $21,815
doi:10.1371/journal.pntd.0000708.t005
Table 6. Total costs prevented per individual of the Benefit Cohort Population.
Population Group Population Subgroup
Benefit Cohort
Population
(millions)
Total Costs
Prevented
(US$MM)
Lifetime
Benefit per
Individual
Avg. Annual
Lost Work Days
Prevented
Avg. % of Annual
Lost Work Days
Prevented
1. Protected from
acquiring infection
(and subsequent
disease)
a) Newborns 2.2 $1,727 $783 20 6.7%
b) Protected from infection 0.5 $633 $1,319 39 13.1%
Subtotal 2.7 $2,360 $879 23 7.7%
2. Protected from
disease progression
a) Subclinical morbidity 9.4 $14,544 $1,552 36 12.1%
b) Clinical morbidity 19.3 $4,911 $255 8 2.5%
Subtotal 28.7 $19,455 $679 19 6.2%
Total 31.4 $21,815 $696
1 19
1 6.3%
1
1Weighted average of all Benefit Cohort Population subgroups.
doi:10.1371/journal.pntd.0000708.t006
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the effects of DEC on individuals with overt clinical disease show
greater evidence towards the lessening of ADL episodes than the
reduction or reversal of the chronic condition. If future studies
can demonstrate unequivocal benefits of MDA for chronic
disease patients, its proportion of economic benefits will be even
higher.
Identifying benefits per region. Table 7 highlights the
regional variation in cost savings among GPELF programs. Much
of the difference in per person benefits can be attributed to higher
average costs and wages outside of the AFRO and SEARO regions.
The total GPELF benefits, however, are heavily concentrated in
SEARO and inparticularinIndia,whichcomprisedover75%ofall
individuals treated during the 8-year period.
Economic Benefits to Health Systems
Economic benefits to national health systems resulting from
reduced LF infections derive particularly from patient service costs
averted in the public sector. Approximately US$2.2 billion in
health system costs will be saved over the lifetime of the benefit cohort
population (Table 8). Combined with the US$21.8 billion savings
for individuals, the total economic benefit following the first 8
years of the GPELF is estimated at an extraordinary US$24.0
billion (Figure 4).
Sensitivity Analyses
This overall economic analysis of the GPELF’s first 8 years does
have notable limitations due to the lack of regionalized primary
data concerning both epidemiological and socioeconomic factors
associated with LF. Indeed, two sections of the model remain with
particular uncertainty: 1) The degree to which MDA can reverse or return
an individual with overt clinical disease to regular productivity, and 2) The
relationship between hours lost and output/productivity lost due to disease.
The total estimated economic impact is particularly sensitive to
these variables because of the large number of clinical disease
patients receiving MDA and the high proportion of total prevented
Figure 3. Total Economic benefits by category. The total economic benefit for individuals (i.e. excluding health system savings) of US$21.8
billion can be further analyzed by cost type, morbidity type, and clinical presentation.
doi:10.1371/journal.pntd.0000708.g003
Table 7. Lifetime economic benefits by region.
WHO Region
Total Lifetime
Benefit (US$MM)
1
Lifetime Benefit
per Patient
Avg. Annual Lost
Work Days Prevented
Avg. % of Annual Lost
Work Days Prevented
AMRO $183 $1,446 20 6.7%
AFRO $1,288 $439 23 7.5%
EMRO $146 $922 20 6.6%
WPRO $2,128 $2,186 18 6.0%
SEARO $18,070 $665 19 6.2%
All
2 $21,815 $695 19 6.3%
1Does not include health system benefit.
2Weighted average over all WHO regions.
doi:10.1371/journal.pntd.0000708.t007
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analyses were carried out to assess the range of economic benefits that
can be achieved under varying estimates of each variable. Secondary
sensitivity analyses investigating the frequency and duration of ADL
episodes, and direct treatment costs indicated less variability of
economic benefits when adjusting these parameters.
Chronic disease regression and reversal with MDA. As
noted previously, there is considerable debate about the degree of
regression of existing hydrocele and lymphedema following MDA
treatment. Estimates range from no regression at all to complete
reversal of 87% of hydrocele cases and 69% of leg lymphedema
cases after 5 annual rounds of DEC with ivermectin or DEC alone
[24]. Other estimates from related studies also lie within this range
[25,26,27,28,31,55], which is therefore used as the lower and
upper boundaries for the sensitivity analysis. A linear relationship
will also be assumed – i.e. that a 50% reversal of chronic disease
would lead to an average 50% increase in the potential lost
aggregate working hours for a chronic disease patient over his or
her entire remaining lifetime.
Table 9 compares the degree of chronic disease reversal to the
total economic benefit gained by the clinical disease population. In
our model, US$21.8 billion would be saved based on 10% of
hydrocele and 15% of lymphedema cases considered curable
through MDA. If these estimates even double to 20% and 30%,
respectively, the total amount rises to US$24.4 billion, equivalent
to approximately 7.2% of annual income for inidividuals of the
benefit cohort population. Under the maximum assumptions based on
the data of Bockarie et al. [24], total economic benefits would be a
staggering US$37 billion or 11.0% of individual annual income.
With such a varying degree of potential economic impact that is
also likely dependent on parasite and MDA regimen type, a better
understanding of the true relationship between antifilarial drug
treatment and filarial morbidity is needed. In particular,
prospective studies with rigorous case definitions, close clinical
monitoring, control groups, and outcomes focused on clinical
morbidity rather than microfilaria prevalence alone [32], would
strengthen our understanding of this relationship. Nevertheless,
that there exists scientific data supporting chronic disease
Figure 4. Cumulative economic benefits resulting from the first 8 years of the GPELF. Total economic savings to individuals and health
systems accumulate throughout the benefit cohort population’s lifetime.
doi:10.1371/journal.pntd.0000708.g004
Table 8. Health system economic benefits.
WHO Region
Benefit Cohort
Population
(millions)
% Seeking
Treatment at
Gov’t Primary
Health Center
1
Cost per 20 Minute
Outpatient Visit to
Government Primary
Health Center
2
Total 2008
Health System
Cost Averted
(US$MM)
Total Lifetime Health
System Costs Averted
(US$MM)
AMRO 0.1 52% $3.7 $0.2 $4.3
AFRO 2.9 52% $2.4 $2.7 $53.5
EMRO 0.2 52% $2.1 $0.1 $3.8
WPRO 1.0 52% $4.0 $1.4 $39.8
SEARO 27.2 52% $2.2 $81.0 $2,085.7
All Regions 31.4 52% $2.3 $85.5 $2,187.1
1Weighted between acute and chronic disease patients across all GPELF countries within WHO region.
2Using WHO-CHOICE estimates. Weighted average for all GPELF countries within region.
doi:10.1371/journal.pntd.0000708.t008
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studies in this regard will be essential to determining the full
economic impact of MDA on the clinical manifestations of
hydrocele and lymphedema.
Indirect productivity loss due to clinical LF. Our analysis
calculates indirect costs based on the equivalent hours and
resulting wages lost from economic activity. This approach,
however, ignores how much output and productivity are actually lost
as a result of fewer work hours. In a study of Indian weavers, the
reported productivity gap between LF and non-LF individuals was
27% [56], which is markedly higher than the 15–20% time
difference used for measuring indirect costs from chronic disease in
this study. In defense of the analysis, time valuation was utilized on
its own because supporting primary data on productivity burden
was absent from the literature. Moreover, Ramu et al.’s study [56]
evaluated the productivity of weavers whereas compared to
farmers, output is not predicated on seasonal and environmental
factors that would cause increased correlation variation between
time and output. Nevertheless, this distinction between time and
productivity burden would likely only underestimate the true
disability and loss of earning power for individuals with clinical
disease.
At our base rate of 15–20% productivity loss averted, the total
lifetime benefit for the benefit cohort population is US$21.4 billion. By
increasing this rate to 30%, the total lifetime economic benefit rises
almost 75% to US$36.4 billion, equivalent to 10.6% of individual
annual income. This high sensitivity to chronic indirect costs
indicates that additional research on the actual productivity and
economic output burden of LF, rather than time alone, will bring
significant value to developing a more precise economic benefit
estimate in the future.
Similarly, chronic disease indirect costs are particularly sensitive
to the average earnings of individuals with LF. This study chose to
estimate conservatively by basing a wage on the minimum income
amounts listed for agricultural workers using 3 separate database
sources – the ILO’s LABORSTA database [11], the World Bank’s
World Development Indicators Online [12], and minimum wage
estimates from the International Labour Organization [13] and
the US Department of State’s Country Reports on Human Rights
Practices 2008 [14]. If instead only World Bank wages were used,
the average wage, weighted across all regions, would increase from
$1.05 to $1.40 and the total economic benefit estimated in this
model would rise from $21.4 billion to $28.8 billion, which is 8.4%
of individual annual income. If only ILO wages were implemented
in the model, the average wage would be $1.50 and the total
economic benefit $30.7 billion or 9.0% of individual annual
income. Additionally, LF patients may be employed in occupa-
tions earning more than subsistence farmers (e.g. weaving, mining,
fishing) and therefore suffer a higher opportunity cost of illness.
Average incomes are also generally higher in urban areas, where
up to a third of the LF burden in India exists [46,57]. More
socioeconomic research of LF patients will be necessary to yield
greater accuracy of the opportunity cost of the disease and indirect
economic benefits of the GPELF.
Acute episodes. Acute ADL episodes are notably
debilitating and clearly inhibit economic activity. Therefore, the
number and duration of annual ADL episodes prevented has an
impact on both direct and indirect economic benefits. In this
study’s base model, it is estimated that individuals with hydrocele
incur on average 2 ADL episodes per year and for lymphedema
patients, 4 episodes per year. Previous studies have shown the
annual incidence can vary from 1 to 8 [33,45,58], resulting in a
range of total economic benefits of $19.0 billion to $25.6 billion
(5.5% to 7.4% of individual annual income). The economic
impact is also dependent on the average duration of ADL
episodes, which can last from 2 to 16 days. The upper end of this
range would lead to economic benefits totaling $32.2 billion
(9.4%) with a more modest increase in average duration of 6 and
8 days resulting in benefits of $23.3 billion and $25.0 billion,
respectively (6.8%–7.3%). On the lower end, assuming ADL
episodes last an average of only 2 days decreases the total
economic benefit to $19.8 billion (5.8%).
Direct treatment costs. The results from Figure 3 show
that prevention of direct treatment costs constituted only 6.2%
of the total economic benefit. Therefore, while previous
research indicates a large variance in the cost, source, and
frequency of treatment, the economic benefit outcome is not as
sensitive to these variables as with chronic indirect costs. While
there are reported cases of LF pati e n t si np r i v a t eh o s p i t a l so r
using multiple treatment sources spending up to $40 per ADL
episode [31,51] or $200 per year [37] for chronic disease
treatment, these instances represent extreme outliers given that
the mean costs associated with the reviewed literature typically
range from $1–$5. If we were to double the average prevented
costs of treatment for ADL episodes, hydrocele, and
lymphedema, the total economic benefit would marginally rise
to $22.9 billion (6.7% of individual annual income). Tripling the
average treatment cost would result in an economic benefit of
$26.2 billion (7.6%), which is a far less elastic outcome than
when varying the parameters of chronic indirect costs or even
the frequency of ADL episodes.
Table 9. Sensitivity analysis for chronic disease reversal following MDA.
Selected Studies
Hydrocele
Reversal/
Improvement
Hydrocele
Patients (n)
Lymphedema
Reversal/
Improvement
Lymphedema
Patients (n)
Estimated Economic
Benefit Based on Study
Parameters (US$MM)
Avg, % of Annual
Lost Income (Work
Days) Prevented
Ciferri 1960, Dunyo 2000, Das 2003
1 0% 37 0% 26–48 $18,890 5.5%
Partono 1985 - - 71% 49 $27,590 8.0%
Partono 1981 - - 75% 20 $28,010 8.1%
Mackenzie 2009 15% 13 98% 62 $31,020 9.0%
Meyrowitsch 1996 67% 60 39% 26 $31,700 9.2%
Bockarie 2002 87% 105 69% 90 $37,390 11.0%
Base model estimates 10% - 15% - $21,815 6.3%
1No change or results considered insignificant.
doi:10.1371/journal.pntd.0000708.t009
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Goldman et al. found the average annual economic cost per person
treated (i.e. including the implied costs of donated materials and
drugs – set at US$0.19+$0.0019 for shipping per 400mg tablet of
albendazole and US$1.50+$0.0018 per 3mg tablet of ivermectin)
ranged from US$0.40 in Philippines to $5.82 in Tanzania. The
average annual financial cost per person treated (i.e. excluding the
costs of the donated materials and drugs) ranged from US$0.06 in
Burkina Faso to US$1.34 in Haiti [54].
One-year economic benefits per person treated in this study
ranged from US$1.00 in Burkina Faso to US$4.56 in the
Dominican Republic. Table 10 compares these economic benefit
estimates with the economic and financial costs from Goldman et
al.’s study to calculate country-specific BCRs. The economic cost
BCR for the three African countries using the ivermectin+alben-
dazole regimen are lower (0.21–0.37) than those in countries using
DEC+albendazole (1.23–8.59). Since the drugs, however, are
available at no cost to the GPELF, BCRs calculated using financial
costs are more favorable, ranging from 1.64 in Egypt to 18.07 in
the Philippines.
Discussion
LF is a pervasive, disabling disease whose importance is
magnified by the fact that 1.3 billion people are at risk of infection
in some of the poorest countries in the world. LF causes not only a
severe physical burden on sufferers but also a considerable
economic burden from both direct medical expenses and loss of
income-generating activity. While precise data on the economic
burden of LF morbidity have been scarce [59], it was the earlier
estimate of disease impact resulting in US$1 billion in lost
productivity each year in India alone [46] and another $1 billion
combined for the endemic countries in Africa [60] that
contributed to the World Health Assembly’s resolution for the
elimination of LF and WHO’s subsequent creation of the Global
Programme to Eliminate Lymphatic Filariasis (GPELF) [61].
The present study constitutes the first attempt to quantify the
principal economic benefit of the first 8 years of the GPELF and, as
such, complements an earlier analysis on the health impact of
these first 8 years [1]. It conservatively estimates that in 2008
alone, over US$775 million of direct and indirect patient costs
were averted as a result of MDA in 48 endemic countries. Of the
570 million individuals treated in the MDAs, 31.4 million either had
clinical disease or would have acquired clinical disease during
these 8 years. In the entire lifetimes of these 31.4 million people, costs
totaling of US$21.8 billion (an average of nearly US$700 per
person) will be averted. On a per person-year basis, this translates
to approximately 6.3% of one’s average annual income after future
discounting.
In the absence of MDA, much of the economic burden can be
attributed to indirect costs in the form of lost labor time. ADL
episodes exacerbate the chronic pathology of lymphedema and
hydrocele, and can lead to total disability for the entire duration of
81–87% of acute attacks [40,51]. The economic burden is also
greater should ADL episodes occur more frequently during the
critical planting seasons for agricultural workers, which evidence
from some literature suggests is the case [41,44,62,63].
Despite this greater severity and incapacitation of ADL, it is the
lifelong disabling nature of the chronic conditions that makes LF
such an economically crippling disease. In calculating the total
indirect costs of chronic disease, this study estimated that over 1
billion working hours each year would have been foregone without
MDA. At an estimated 15–20% reduction in daily work hours,
approximately 6–8% of equivalent workdays are lost annually to
chronic disease. Related studies from Ghana and India indicate
3.8% and 7.0% of all potential male labor inputs, respectively,
were lost annually as a result of chronic LF [38,40].
Direct treatment costs, while much less than the indirect cost of
lost labor, are still significant. Direct costs are especially
burdensome because an acute or chronic disease patient may
need to borrow money to pay for treatment or, more commonly,
must avoid treatment altogether because it is unaffordable.
Estimates from the literature suggest that only 60–70% of ADL
and 40–50% of chronic disease sufferers on average, sought
treatment (including self-treatment) – highlighting a tradeoff
between financial and physical burden. In this study, the average
Table 10. Country-specific benefit-cost ratios.
Economic Benefit - Financial Cost
1 Economic Benefit - Economic Cost
2
Country Year
MDA
Round
Avg. Economic
Benefit per Person
Treated (1-year)
3
Financial Cost per
Person Treated
4
Benefit-Cost
Ratio (1-year)
Economic Cost per
Person Treated
4
Benefit-Cost
Ratio (1-year)
Burkina Faso* 2002 2 $1.00 $0.06 16.67 $4.82 0.21
Ghana* 2002 2 $1.82 $0.17 10.72 $4.88 0.37
Tanzania* 2003 4 $0.99 $0.26 3.81 $4.53 0.22
Dominican Republic 2003 2 $4.56 $0.87 5.24 $1.56 2.92
Egypt 2001 2 $1.64 $1.00 1.64 $1.34 1.23
Haiti (Leogane) 2002 3 $2.84 $1.30 2.18 n/a -
Haiti (Milot) 2002 1 $3.60 $1.10 3.27 n/a -
Philippines 2003 3 $3.43 $0.19 18.07 $0.40 8.59
1Financial cost does not include the cost of ivermectin and albendazole, which are both donated. DEC must be purchased by national programs and is therefore
included as a financial cost. Ivermectin is used in combination with albendazole in areas co-endemic for onchocerciasis in Africa plus Yemen. DEC, which is not
donated, is used in combination with albendazole in all other countries and must be purchased by national programs.
2Economic cost includes the implied cost of donated materials and drugs (Source: Goldman et al. (2007) [54]): US$0.19+$0.0019 for shipping per 400mg tablet of
albendazole and US$1.50+$0.0018 per 3mg tablet of ivermectin.
3Includes both individual and health system benefits. Currency is adjusted to match year of MDA round.
4Source: Goldman et al. (2007) [54].
*Countries receiving the albendazole+ivermectin drug regimen.
doi:10.1371/journal.pntd.0000708.t010
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is almost 1.5 times greater than the estimated average daily
income. Treatment in private facilities or using multiple treatment
sources, however, can range up to 10 or more times this amount.
In reality, costs can vary even more as some cases in India and
Tanzania reported spending nearly $40 per ADL episode [31,51].
The same extent of the range of direct costs can be found for
chronic disease patients. A study in eastern India reported
treatment costs upwards of $200 per year [37]. While treatment
seeking behavior is likely to be higher in a patient’s early years with
chronic disease, it is still reasonable to assume that direct treatment
costs will be sustained in a patient’s later years because the chronic
manifestations themselves will progress with age. Along with this
progression, the need for other forms of treatment and pain
management will remain.
LF is recognized as one of the most important neglected tropical
diseases (NTDs), which are often characterized as diseases of
poverty. Indeed, it is clear that the considerable losses in labor
inputs from LF over a prolonged period of time make it all the
more difficult for endemic areas to escape from such a poverty trap
without MDA intervention. Although chronic disease patients may
develop coping strategies to adapt to their condition and regain
some time spent in economic activity, many do so at the expense of
lower-earning jobs that require less physical activity [38,64]. In
Tanzania, it is roughly reported that patients who were primarily
fishermen lose about 53% of their income each month due to
chronic LF disease [65]. Those with severe morbidity may be
confined to the home and forced to give up income-generating
activity altogether.
Proponents of the friction-cost method of indirect cost
calculation would argue that substitute labor could replace the
lost inputs and outputs of an LF patient [66]. However, with most
LF patients working outside the formal economy, other family
members would have to act as substitute labor, which often
subtracts the same proportion of household income. For example,
a study on the economic burden of malaria found household
members more likely to care for the patient than act as substitute
labor, particularly when skilled labor is involved; when substitution
did happen, output was not perfectly replaced [67]. Friction-cost
theorists also argue that lost hours can be made up by extra
productivity during non-sick hours; however, reduced labor inputs
in time-sensitive activities such as agricultural planting cannot be
so easily replaced later on. LF studies indicate that it may even be
necessary for sick individuals to hire temporary workers to replace
their labor, thus exacting an even greater indirect financial burden
on the patient.
In analyzing the economic impact for the 31.4 million benefit
cohort population, this study estimates that individuals receiving
MDA before infection or at the subclinical disease stage have a
much higher average lifetime and annual economic benefit than
individuals already manifesting clinical disease (Table 6). With
advanced stages of hydrocele and lymphedema posing even
greater risks of physical and economic disability [39], MDA at the
pre-infection or pre-clinical disease stage is critical, particularly in
high-transmission areas. Furthermore, high coverage rates in areas
undergoing MDA allow a subgroup of untreated individuals to be
protected from infection, subsequent clinical disease, and the
incurrence of economic costs as a result of reduced rates of LF
transmission. The extension of benefits to individuals beyond those
directly receiving MDA or infected with LF accentuates the wider
community economic impact of the GPELF.
This broader impact also includes financial savings to national
health systems as a result of decreased need for patient services
associated with LF morbidity. Using WHO-CHOICE’s valuation
of health center outpatient visits [52], MDA from 2000–2007 will
lead to an estimated economic benefit of approximately US$2.2
billion over the same timeframe as calculated for the 31.4 million
benefit cohort population. Such significant savings are particularly
critical for resource constrained health systems and primary health
centers operating beyond capacity. The economic benefits to
health systems are arguably even greater than the estimate
presented in this analysis. This model did not account for the effect
of MDA on decreasing the need for hydrocele surgeries and
lymphedema morbidity-support services because accurate region-
alized data on the extent of averting these specific provider costs is
limited. From the scarce literature available, hospitals in Tanzania,
coastal Kenya, and northern Ghana have reported that 15–25% of
all surgeries performed were for hydrocele [68,69] and that
establishing a single lymphedema treatment clinic in Haiti can cost
the health system US$8,000 [70]. In India, the additional cost of
implementing filariasis control programs at the primary health
center (PHC) level was estimated at approximately US$800 per
PHC per year [71]. Limiting the future need for such services will
bring sizable cost savings for both national filariasis control
programs and health systems, which further underscores the
GPELF’s societal economic impact.
Cost-Benefit Calculations
In Table 10, the BCRs calculated with economic costs are low,
particularly for the African countries using the ivermectin+alben-
dazole regimen. In reality, however, the whole foundation of the
GPELF is the long-term, sustained commitment of drug donations
offered by GlaxoSmithKline for albendazole and Merck & Co.,
Inc. for ivermectin for as long as needed until LF is eliminated
[72,73]. Because of this commitment, governments and donors
will never have to finance these costs themselves; indeed, without
these commitments there would be no GPELF. Therefore,
understanding the financial costs (i.e. excluding the costs of the
donated materials and drugs) to the GPELF is more relevant for
policy- and decision-making than is the analysis of economic costs.
When comparing financial costs to economic benefits, then, Table 10
shows very favorable BCRs, including up to 18.07 in the
Philippines.
Whether examining financial or economic costs, the BCR
becomes larger in the years beyond the recommended 5 rounds of
MDA to achieve lifetime protection from LF. The Goldman et al.
study [54] showed strong evidence that costs decrease after the
initial year of implementation and after 5 rounds of MDA, the
drug costs and majority of program activities would arguably
subside dramatically as well. In the Philippines for example, by
conservatively extrapolating the initial year’s annual economic cost
over 5 years, the cost to lifetime benefit ratio indicates that a $1
investment leads to a sizable return of $60 per individual treated.
While this analysis does not account for costs following the 5
th
round of MDA (e.g. post-MDA surveillance), it can be reasonably
assumed that the BCR would still remain very significant. Indeed,
even if annual economic costs were to persist at an equivalent rate for
an additional 10 to 15 years, the economic rate of return per
person treated is still approximately $20–$30 for every $1 invested.
Comparing the cost-benefit of the GPELF to that of other NTD
programs is difficult because there are few directly comparable
analyses, particularly at a global level. A review of the African
Programme for Onchocerciasis Control (APOC) projected an
economic rate of return of 6% to 17% but did not factor in the
implied economic cost of the donated drug [74]. This finding is
less than the drug-excluded LF cost-benefit estimate presented
here, however, several economic benefits apart from onchocercal
blindness prevention were not analyzed in the APOC review.
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on trichiasis surgery in a localized context [75]. A broader array of
cost-benefit studies has been carried out for malaria, although with
differing scopes and outcome goals, making it challenging to
compare results across the same disease, let alone between malaria
and LF. In a review of several malaria costing studies, the BCR
ranged from 1.9 to 17.1 using a variety of human capital and
burden of disease methodologies [76]. Other approaches assessing
a more macroeconomic impact of malaria [77,78] have yet to be
applied to NTDs but future research into such cost-benefit
applications will be critical for validating the investment of the
GPELF and stimulating likeminded investigations for related
global NTD programs.
There has been considerable movement – particularly in Sub-
Saharan Africa – toward integrating preventive chemotherapy
programs to target multiple NTDs (e.g. LF, onchocerciasis,
schistosomiasis, soil-transmitted helminths [STH], trachoma)
together. Although there is no clear verdict yet on the benefits
of integrated NTD treatments versus standalone vertical pro-
grams, early assessments indicate potential savings of 25–47% for
the entire group of NTDs can be achieved in Sub-Saharan Africa
by packaging MDA interventions together [79]. These findings
underlie an important concept of economic analysis, specifically
that although an intervention (e.g. vertically integrated MDA
programs for LF) may have a favorable BCR, there may be more
cost-effective alternatives to achieving a similar outcome (e.g. the
number of treatments administered, the total economic benefits of
the GPELF). In this respect, the GPELF is well positioned to take
advantage of synergistic opportunities with other disease program
activities including vector control (malaria and dengue fever),
surveillance (guinea worm, onchocerciasis), and distribution
(integrated NTDs, Vitamin A) to maximize cost-effectiveness
and economic impact [80]. Joint efforts with the private sector and
drug development projects addressing improved sanitation and
housing facilities could also contribute to greater cost-effectiveness
for the GPELF [81]. While this study is not positioned to analyze
cost-effectiveness in details, it is abundantly clear that under any
joint or standalone scenario, the GPELF indeed represents an
excellent buy in global health.
Additional Economic Benefits of the GPELF
The prevention of LF infection and clinical disease has led to
additional benefits that are difficult or impossible to quantify in
monetary terms. The true economic value of the GPELF is,
therefore, arguably much higher based on the numerous quality-
of-life benefits achieved through clinical disease aversion, as well as
the economic impact that MDA has on other diseases and
syndromes related to LF.
Quality-of-life benefits. Quality-of-life benefits may relate
only peripherally to the economic burden of the disease but may
be equally as important as the costs included in the model due to
their direct impact on patient livelihood. Social stigma is a very
important consequence of LF morbidity. The ostracism and
isolation that LF patients experience in their communities can lead
to delayed treatment seeking; this results in faster progression to
later stages of morbidity where the economic burden is even
higher [82]. In organized labor, employers may fire patients with
obvious morbidity due to decreased productivity or
misunderstanding of disease etiology. Female patients are often
not considered suitable for marriage if they have lymphedema,
which heavily impacts social and economic status [59,83,84].
Similarly, males with hydrocele report difficulties in finding
spouses, ridicule from community members, and various degrees
of sexual dysfunction [85]. Schoolchildren are expected to stay
home to care for a family member with LF who is experiencing an
acute attack, and infected schoolchildren frequently miss school or
drop out due to ostracism [86]. When LF impacts income-
generating activity of the heads of households, children may be
forced out of school and into labor at an early age. This
absenteeism from school and eventual dropping out maintains the
poverty cycle for affected families and has important implications
for endemic communities as a whole [82]. The efforts of the
GPELF in eliminating these devastating consequences of clinical
disease have created enormous quality of life benefits that have
undoubtedly led to a tremendous economic impact through
enhanced productivity and community welfare.
The GPELF must also be recognized as more than just a MDA-
based distribution program As such, the GPELF’s ‘second pillar’ is
to provide care and initiate strategies for the control of clinical
morbidity [32]. In particular, compliance to GPELF activities
based on personal hygiene management of lymphedema has
caused tremendous improvements in the physical and mental well-
being of chronic disease patients. These improvements surely
produce an unquantifiable economic benefit and reinforce the
notion that even if antifilarial drugs do not have a direct effect on
clinical morbidity reversal, the GPELF has created other
mechanisms for long-term increased productivity for overt clinical
disease patients.
Economic impact on other LF syndromes and co-endemic
diseases. MDA reduces the acquisition of other debilitating
overt clinical LF manifestations such as chyluria and tropical
pulmonary eosinophilia (TPE). While these other syndromes are
less prevalent than hydrocele and lymphedema, their physical and
resulting economic burden can be even more severe.
Socioeconomic data concerning such LF-associated syndromes,
however, is essentially absent and therefore currently
unquantifiable. Also not considered quantitatively was the full
economic impact of subclinical LF infection. By protecting
individuals from even reaching the subclinical level, the GPELF will
have garnered economic benefits from preventing the renal
disease, lymphatic dilatation, and lymphatic dysfunction in
subclinically infected patients [87,88].
The GPELF’s drug regimens also result in decreased economic
costs for other diseases besides LF – including river blindness and
scabies in Africa and intestinal parasites globally. Considering the
disease burden of these three infections and their geographic
overlap with LF, it is certain that an important reduction in these
diseases is found in MDA treatment areas, resulting in health and
economic benefits from prevention and diminution of stunting,
anaemia, renal disease, and other complications [89,90].
Study Limitations
A narrow range of country-specific primary data somewhat
limits the breadth of economic analysis presented in this paper;
however, much of the prevailing literature originates from India
and Sub-Saharan African countries where over 75% of the benefit
cohort population resides. Of significance, there is scarce regional
data regarding treatment-seeking behavior for LF patients, but
because this is a direct cost input, more exact data would result in
only marginal changes to the overall economic impact. Similarly,
LF disease-specific parameters (e.g. ADL frequency and duration,
lost workdays) were attributed a global standardized estimate due
to a lack of regional data. Sensitivity analyses conducted earlier in
this study presented the resulting economic impact under differing
degrees of pathology and indeed, a clearer understanding of
regional variability would enrich future economic analyses. Other
variables such as wages, health system costs, and direct treatment
costs, however, were able to be made region- and country-specific
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World Bank.
Economic Projections for the Future Impact of GPELF
Despite important limitations to our analysis, this study
identifies a wide array of economic benefits that have resulted
from the first 8 years of the GPELF – approximately US$21.8
billion of direct and indirect patient costs will be prevented in the
lifetimes of more than 31 million individuals, US$2.2 billion of LF-
associated patient services saved by national health systems over
the lifetimes of the MDA-treated individuals, and additional
quality-of-life benefits and treatment of co-morbidities such as
STH that make the total economic value of the GPELF
unquestionably far greater than the calculable estimate presented
here.
These achievements notwithstanding, it is clear that the
economic impact will be even greater when the GPELF reaches
the remaining endemic countries and at-risk populations.
Currently, the GPELF has extended to 48 of the 83 endemic
countries and treated nearly 570 million individuals – approxi-
mately 44% of the ,1.3 billion worldwide at-risk population [8].
Extrapolating this proportion with the US$24 billion lifetime
economic benefit already achieved, the full potential economic
benefit of the GPELF could be in excess of US$55 billion
distributed over each of the endemic WHO regions (Figure 5).
Reaching the remaining at-risk individuals presents notable
challenges especially since much of the population not yet reached
resides in some of the poorest countries in Africa. Additional
resources and economic empowerment will be necessary to assist
these countries in implementing programs for LF elimination [91].
The expansion of the GPELF will therefore be a critical building
block in this effort and also an important driver for increased
attention to NTDs and the continuation of integrated NTD
programs. The recognition of the sizable monetary benefit already
achieved after 8 years provides new confidence that it is an
investment well worth undertaking.
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